top of page

Biomarkers Associated With Anti-PD-1/PDL-1 Therapies

Farcast has curated a universe of 549 biomarkers including differential gene/protein in the tumor microenvironment, mutations, epigenetic modifications, immune cell sub-populations, signaling pathway signatures and peripheral plasma factors. Of these, 379 are associated with response while 170 are associated with resistance to PD-1/PD-L1 therapy. This curated set of biomarkers is linked with 21 tumor histologies with melanoma being the most studied followed by lung cancer, breast cancer, renal cell carcinoma (RCC) and several others.

bottom of page